Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 913-920

  Viana Pereira, Marta ^a   Lopes, José Manuel ^b   Little, Suzie ^d   Milanezi, Fernanda ^a,b   Basto, Diana ^a   Pardal, Fernando ^c   Jones, Chris ^d   Reis, Rui Manuel ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c S Marcos Hospital   (Portugal)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Amplification; EGFR; EGFRvIII; Glioblastoma; Glioma; Oligodendroglioma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULAR DYNAMICS; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PORTUGAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 42549104976     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Benin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
3. Benjamin R, Capparella J and Brown A: Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 9: 82-90, 2003.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
5. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
6. Kuan CT, Wikstrand CJ and Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8: 83-96, 2001.
7. Nicholas MK, Lukas RV, Jafri NF, Faoro L and Salgia R: Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12: 7261-7270, 2006.
8. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
9. Combs SE, Heeger S, Haselmann R, Edler L, Debus J and Schulz-Ertner D: Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 6: 133, 2006.
10. Diasio RB and Fourie J: Targeting the epidermal growth factor receptor in the treatment of colorectal cancer - state of the art. Drugs 66: 1441-1463, 2006.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
12. Nieder C, Schlegel J, Andratschke N, Thamm R, Grosu AL and Molls M: The role of growth factors in central nervous system tumours. Anticancer Res 23: 1681-1686, 2003.
13. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W and Collins VP: Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 149: 29-35, 1996.
14. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kemshead JT and Vega F: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169-174, 1995.
15. Schwechheimer K, Huang S and Cavenee WK: EGFR gene amplification - rearrangement in human glioblastomas. Int J Cancer 62: 145-148, 1995.
16. Rao RD, Uhm JH, Krishnan S and James CD: Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci 8: e270-e280, 2003.
17. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR and Bigner DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4: 148-158, 1998.
18. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS and Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005.
19. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL and Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024, 2005.
20. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, Pardal F, Suriano G, Machado JC, Lopes JM and Reis RM: Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 13: 2621-2626, 2007.
21. Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Savary J and Sabourin JC: Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep 16: 1173-1179, 2006.
22. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR and Schmitt FC: EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209: 445-453, 2006.
23. Biernat W, Huang H, Yokoo H, Kleihues P and Ohgaki H: Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14: 131-136, 2004.
24. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y and Ushio Y: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962-6970, 2003.
25. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB and James CD: Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63: 700-707, 2004.
26. Marquez A, Wu R, Zhao J, Tao J and Shi Z: Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13: 1-8, 2004.
27. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991.
28. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG and Aldape K: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61: 1122-1128, 2001.
29. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH and Bigner DD: Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48: 1103-1110, 2000.
30. Wikstrand CJ, McLendon RE, Friedman AH and Bigner DD: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57: 4130-4140, 1997.
31. Franco-Hernandez C, Martinez-Glez V, Alonso ME, de Campos JM, Isla A, Vaquero J, Gutierrez M and Rey JA: Gene dosage and mutational analyses of EGFR in oligodendrogliomas. Int J Oncol 30: 209-215, 2007.
32. Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B and Bigner DD: Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol 47: 191-205, 1988.
33. Ohgaki H and Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489, 2005.
34. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN and Nutt CL: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65: 1181-1188, 2006.
35. Dirks PB and Rutka JT: Current concepts in neuro-oncology: the cell cycle - a review. Neurosurgery 40: 1000-1013, 1997.
36. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R and Aldape K: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11: 1462-1466, 2005.
37. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD and Aldape K: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25: 2288-2294, 2007.
38. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
39. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A and Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32: 74-89, 2006.
40. Barber TD, Vogelstein B, Kinzler KW and Velculescu VE: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351: 2883, 2004.
41. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K and Delattre JY: EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64: 1444-1445, 2005.
42. Lee JC, Vivanco I, Beroukhim R, Huang JHY, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M and Mellinghoff IK: Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine 3: 2264-2273, 2006.
43. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Rasheed BKA, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD and Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133-142, 2004.
44. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crino L and Brandes AA: Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96: 1047-1051, 2007.
45. Vogelbaum MA, Peereboom D, Stevens G, Barnett G and Brewer C: Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: Interim results. J Clin Oncol 22: 121 (suppl.) (abstract), 2004.
46. Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Klencke B and Mischel P: Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 23: 115 (suppl.) (abstract), 2005.
47. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard L, Torres O, Marinello P, Perez R and Lage A: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3 - Report from a phase I/II trial. Cancer Biol Ther 5: 375-379, 2006.
48. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM and Furnari FB: The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13: 1911-1925, 2007.